Seventure Partners has published a report on the research advances in the human microbiome in 2023.
It includes the main implications on health, progress of clinical studies and therapeutic, diagnostic and nutritional products.
The report, entitled "Microbiome Progress: A look at 2023", provides an overall assessment of research and developments linked to the human microbiome across the globe, to define the state of play at the end of 2023.
It includes analyses and predictions for the fields of therapeutics and nutrition in the short, medium and long terms, and summarises the scientific publications made in 2023 in these areas, with their key take-home messages.
The main themes of the report include:
- The development, composition and link between the intestinal microbiome and human health: immunity, chronic diseases, etc.
- Progress in targeting the composition and function of the microbiome for the treatment of autoimmune, inflammatory, metabolic, and neurological diseases. Advanced results seen already in the treatment of cancers, autism, Parkinson's disease, and obesity.
- Data standardisation and adoption of machine learning and artificial intelligence technologies to accelerate data processing and research.
- Perspectives of the first generation of microbiome products, faecal microbiome transplantation, and next-generation products, such as Live Biotherapeutics Products (LBP) and more traditional drugs.
- Targeting human microbiomes other than the intestine: oral cavity, skin, vagina, and lungs.
- Non-medicinal products: prebiotics, probiotics, postbiotics, symbiotics, etc.
“Research on the human microbiome has seen sustained development in 2023, and major progress has been seen in therapeutic targeting,” explains Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, and author of the report.
“Several drugs have now obtained regulatory marketing authorization and although there have been some inconclusive clinical studies, numerous human trials have demonstrated encouraging effectiveness across multiple diseases. This year and in the future, I expect to see a continued acceleration in research and marketing of medicinal and non-medicinal products in the field.”
